



Background: The number of patients requiring renal replacement therapy (RRT) worldwide has been on the rise. 
Vascular access is the lifeline for these patients when haemodialysis (HD) is the treatment of choice. Access-related 
morbidity is a leading cause of hospitalization so that the function and patency of access are essential for the optimal 
management of patients. There is a need to recognize when a vascular access is dysfunctional because intervention 
must maintain function as well as preserve future vascular access sites.
Methods: This was a cross-sectional study that evaluated the haemodialysis vascular access function in patients 
undergoing chronic haemodialysis at the Kenyatta National Hospital, Nairobi, Kenya. Peak access blood flow rates, 
urea reduction ratio (URR) and Kt/V were analysed in 150 patients.
Results: The temporary (non-tunnelled) central venous dialysis catheters had poor function, with only 48% 
 achieving a mean blood flow rate > 300 mL/min. The comparable rate for arteriovenous fistulae (AVF) was 88% 
and for tunnelled dialysis catheters 82%. One-quarter of the patients had a URR < 65%. Higher mean blood flow 
rates were associated with higher URR (P = 0.004) and Kt/V (P = 0.009) values. AVF stenosis was present in 12.5% 
and thrombosis in 3% of patients. Aneurysms were the commonest AVF complication (47%) but were not 
haemodynamically significant.
Conclusions: Tunnelled haemodialysis catheters offered adequate blood flows and achieved adequate delivered 
dialysis, comparable to arteriovenous fistulae. Non-tunnelled catheters delivered poor blood flow rates and dialysis 
dose. Greater blood flow rates were associated with a higher delivered dialysis dose. There is a need for routine 
surveillance and affordable interventional procedures to prevent loss of vascular access. 
Keywords: haemodialysis; vascular access; Kenya; adequacy of dialysis.
ORiginal  aRtiCle
Haemodialysis vascular access function in dialysis 
patients at the Kenyatta National Hospital
Florentius O Ndinya1,2, Joshua K Kayima1,2, Peter C Magabe3, Seth O McLigeyo1,2, Antony J Were1,2, George O Odinya2
1Department of Clinical Medicine and Therapeutics, University of Nairobi, Kenya; 2Kenya Renal Association; 3Department of Diagnostic 
Imaging and Radiation Medicine, University of Nairobi, Kenya. 
INtrODUctION
The worldwide prevalence of chronic kidney disease is 
estimated to be between 8% and 16%. It is expected 
to rise disproportionately in developing nations, driven 
by diabetes and hypertension [1]. Renal replacement 
therapy (RRT) in the form of dialysis or renal trans-
plantation is life-saving for patients who progress to end-
stage renal disease (ESRD). The number of patients with 
ESRD requiring renal replacement therapy has continued 
to increase worldwide [1-4]. 
In the year 2010, between 4.9 and 9.7 million people 
were estimated to require RRT; only 2.6 million received 
treatment. This treatment gap is fuelled by the growing 
populations from low-income nations in Africa and Asia. 
The number of people on RRT is projected to more than 
double to 5.4 million people by the year 2030 [5]. 
Around the world, 70% to 80% of patients who need 
RRT are initiated on haemodialysis (HD). In some parts 
of the world, such as Hong Kong and Mexico, peritoneal 
dialysis predominates as the preferred modality of 
RRT [6]. Vascular access is the lifeline for patients on HD 
and its function and patency are essential for efficient 
treatment. Low blood flow rates through the access and 
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loss of patency limit HD delivery, may result in extension 
of treatment times and result in under-dialysis, leading to 
increased morbidity and mortality [7]. 
Measures to prevent access dysfunction include catheter-
locking solutions (with heparin or citrate) and monthly 
blood flow rate surveillance for both central venous 
catheters (CVC) and arteriovenous fistulae (AVF). Measures 
to restore blood flow once dysfunction ensues include 
saline flushes, use of fibrinolytics, mechanical disruption of 
fibrin sheaths for CVCs and fistuloplasty or stenting for 
patients with an AVF [8,9]. 
Access function can also be assessed by measuring the 
delivered dialysis dose. One method is calculation of Kt/V, 
where K = urea clearance, t = dialysis time and V = total 
body water. This index reflects the efficiency of dialysis and 
has been shown to correlate with morbidity and mortality 
of patients on HD [10-12]. Dialysis dose can also be 
assessed by calculating the urea reduction ratio (URR) [13] 
after measuring blood urea concentrations before and 
after dialysis. Achieving a Kt/V ≥ 1.2 or URR ≥ 65% improves 
the outcomes of patients on HD [14] and hence achieving 
this goal remains one of the aims of HD. 
Achieving the targeted dialysis dose may require using 
high-flux dialysers or larger dialysers, increasing the blood 
flow or dialysate flow rates, or increasing the dialysis treat-
ment time. Increasing treatment times and using high-flux 
dialysers cannot be used routinely owing to economic con-
straints as well as patients’ reluctance to spend many hours 
on HD. 
Measuring the flow across the vascular access is an impor-
tant part of ensuring the delivery of effective dialysis [15] 
and we therefore evaluated the vascular access function in 
patients undergoing chronic haemodialysis at our hospital.
MEtHODs
A cross-sectional, descriptive study was conducted 
between January 2016 and March 2016 at the renal unit of 
Kenyatta National Hospital (KNH), in Nairobi, Kenya, on 
patients 13 years or older who had been treated for ESRD 
with haemodialysis for at least one week. Dialysis was 
performed using a Nipro Surdial 55Plus machine or a 
Gambro AK96. Blood flow rates above 300 mL/min are 
prescribed.
The assessment of peak blood flow was performed during 
the first hour of the treatment. A sustained maximum 
blood flow rate for at least 5 minutes was considered the 
peak access blood flow rate. Mean blood flow rate was the 
recorded average for the full HD session. 
Each patient had 2 mL of blood collected pre- and post-
dialysis for urea testing. Samples were analysed using the 
BiOLiS 50i Superior machine. Kt/V was calculated using the 
Daugirdas formula: Kt/V= –ln(R – 0.03) + [(4 – 3.5R) x 
(UF/W)], where UF is the ultrafiltration volume in litres, 
W is the post-dialysis weight in kg, and R is the ratio of 
post-dialysis to pre-dialysis urea [16]. URR (%) was calcu-
lated from the ratio (pre-urea – post-urea)/pre-urea x 100.
Patients with an AVF underwent Doppler ultrasonography 
(using a Sonosite Fujifilm M-Turbo machine and a high-
frequency 9-MHz linear array transducer) of their access 
within two hours of dialysis. The following criteria were 
used for the diagnosis of AVF abnormalities: 
1)   Fistula stenosis: a circumscribed constriction of the 
vessel lumen within the AVF or in the region of the 
colour Doppler flow stream with turbulent high-velocity 
systolic flow and low diastolic flow by spectral Doppler. 
2)   Fistula thrombosis: an echogenic mass (thrombus) pro-
truding into the vessel lumen, associated with partial or 
complete occlusion of the lumen. 
3)   Fistula aneurysm: a circumscribed dilatation of the AVF 
lumen with distinct borders filled with colour Doppler 
flow signals of low velocity. 
The access blood flow for each patient was compared to 
the corresponding URR and Kt/V after the dialysis session, 
to examine the access performance in relation to the 
dialysis dose achieved.  
Ethical approval for the study was granted by the University 
of Nairobi Department of Clinical Medicine and Thera-
peutics and the KNH–UoN Ethics Review Committee 
(reference number P532/08/2015).
rEsULts
From January 2016 to March 2016, 156 consecutive 
patients on haemodialysis were screened for eligibility for 
the study and 150 were included. Approximately half of 
the patients were male (50.7%) and most were young, 
with a mean age of 43 ± 16.5 years. The most common 
documented causes of kidney disease were hypertension 
(40%) and glomerular disease (30%). The duration of 
haemodialysis ranged from 2 weeks to 19 years with a 
median duration of 10.5 months. Approximately three-
quarters of the patients had been on dialysis for less than 
two years.
Table 1 summarizes the vascular access characteristics of 
the study population. The most common form of vascular 
access was a tunnelled central venous catheter (47%), 
followed by non-tunnelled catheters (31%) and AVF (23%). 
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Almost all the patients had been initiated on haemodialysis 
using a central venous haemodialysis catheter. The 
commonest site of insertion was the subclavian vein (87%), 
followed by the internal jugular vein (12%) and femoral 
vein (1%). Arteriovenous fistulae were most commonly 
brachiocephalic (53%) or radiocephalic (44%), and in one 
patient, brachiobasilic (3%). In general, arteriovenous 
fistulae were in use for a longer duration with the longest 
in use for 18 years.
A large proportion of patients (85%) were dialysed twice a 
week. All dialysis sessions were scheduled for 4 hours and 
the mean blood volume processed was 76 L. The peak 
blood flow rates for the group ranged from 180 to 480 mL/
min and the mean blood flow rate, URR and Kt/V were 
311.5 mL/min, 69.8% and 1.5, respectively. The dialysis 
session variables are summarized in Table 2.
Table 3 summarizes blood flow rates, URR and Kt/V 
by vascular access type. Adequate blood flow rates 
(≥ 300 mL/min) were achieved by 88%, 82% and 48% of 
patients using AVF, tunnelled and non-tunnelled catheters, 
respectively. Patients with AVF achieved higher blood flow 
rates and better urea clearances. On Doppler ultra-
sonography, 72% of these AVF patients had blood flows > 
500 mL/min. Lower blood flow rates were associated with 
poor dialysis dose as assessed by URR (Figure 1). On the 
contrary, only 15.1% of patients with a mean blood flow 
rate above 300 mL/min had a URR less than 65%.
Venous aneurysms were the most common complications 
seen in patients with an AVF (47%). Other complications 
observed included 6 patients with anastomotic stenosis. 
Two of these patients had mild stenosis that did not 
affect the blood flow through the access. The prevalence 
of haemodynamically significant stenosis was 12.5%. All 
affected patients had stenosis on the venous side of the 
anastomosis. Two had additional severe upstream stenosis 
with subsequent thrombosis of the access on follow-up 
after one week. High flow rates were seen in 6 patients, of 
whom one presented with a steal syndrome and two with 
venous hypertension. 
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table 1.  Vascular access characteristics of the study 
population (n = 150).   
Current vascular access n (%)
Arteriovenous fistula 34 (23)
Cuffed, tunnelled catheter 70 (47)
Non-cuffed, non-tunnelled catheter 46 (31)
Duration of current access in months Mean (range)
Arteriovenous fistula 50.5 (3.0–222)
Cuffed, tunnelled catheter 8.3 (0.3–43)
Non-cuffed, non-tunnelled catheter 4.6 (0.5–60)
First access n (%)
Arteriovenous fistula 5 (3)
Cuffed, tunnelled catheter 24 (16)
Non-cuffed, non-tunnelled catheter 121 (81)
Reason for change from first access (n = 85) n (%)
 Poor flow 46 (31)
 Infection 11 (7)
 Need for permanent access 28 (19)
table 2.  Dialysis session characteristics (n =150).   
Mean (range)
Frequency of dialysis sessions (%)
  1) Once a week 12.0
  2) Twice a week 85.2
  3) Irregular 2.7
Urea concentration before dialysis (mmol/L) 27.1 (7.8–58)
Urea concentration after dialysis (mmol/L) 8.1 (2.1–31)
Urea reduction ratio (%)                  69.8 (29.6–87.8)
Kt/V 1.5 (0.4–2.5)
Peak blood flow rate (mL/min) 368.3 (180–480)
Mean blood flow (mL/min) 311.5 (175–373.3)
Total volume of blood processed (L)     76.0 (42.0–89.6)
Ultrafiltration volume (L) 2.3 (0.4–5.0)
table 3.  Blood flow rates, URR and Kt/V by vascular  










MBF (mL/min) 330.1 330.1 290.7 < 0.001
MPF (mL/min) 399.2 399.2 336.3 < 0.001
Mean Kt/V 1.6 1.6 1.4 < 0.001
Mean URR (%) 70.9 70.9 67.2 < 0.001
Abbreviation: URR, urea reduction ratio; MBF, mean blood flow rate; MPF,  
mean peak flow rate. 
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Bivariable analysis revealed an association between mean 
blood flow rate and Kt/V (P = 0.006) as well as URR 
(P = 0.004). URR was also associated with age (P = 0.009) 
and weight (P < 0.001). There was no association between 
URR and the type of vascular access (P = 0.078) but there 
was an association between Kt/V and the type of access 
(P = 0.015), age (P = 0.001) and weight both before and 
after dialysis (P < 0.001). 
DIscUssION
Our study population was young and similar to previous 
studies from the Kenyatta National Hospital [17,18]. 
Glomerular disease was the presumed cause of renal 
disease in one-third of the patients. Hypertension was 
common but its presence could be a consequence of 
the renal disease and not necessarily the cause. Most parti-
cipants had been on dialysis for less than 2 years, which 
may reflect a high dropout rate due to the socio-economic 
burden of financing treatment, a high mortality rate, or 
early renal transplantation. 
There has been a shift in vascular access creation and usage 
at the KNH since the late 1980s when arteriovenous shunts 
and arteriovenous fistulae were the predominant forms of 
vascular access for haemodialysis [19]. Central venous 
catheter usage has been on the increase [17] and three-
quarters of the patients in the present study were using 
CVCs. The tunnelled catheter has become an acceptable 
form of long-term vascular access for haemodialysis, 
particularly in settings where arteriovenous fistulae or 
arteriovenous grafts cannot be created [6]. Catheter usage 
in our study was in excess of the NKF–DOQI recommen-
dations that they be used in less than 10% of patients [8]. 
This may be explained by the late presentation of patients, 
the lack of a dedicated vascular surgery team and the 
absence of routine vascular access surveillance. 
Most of our vascular accesses achieved the minimum 
recommended mean blood flow rate (300 mL/min) [8]. 
Higher mean blood flow rates were associated with a high 
delivered dialysis dose. Higher Kt/V and URR values 
were associated with younger age and lower body mass. 
One-quarter of our patients had mean blood flow rates 
< 300 mL/min and this was mostly due to the use of 
non-tunnelled catheters. Poor delivered dialysis dose, as 
determined by URR and Kt/V, was observed in one-fifth to 
one-quarter of patients. Almost all patients with mean 
blood flow rates < 250 mL/min recorded poor delivered 
dialysis dose.  
In a multi-centre study in Iran of 4004 patients, the mean 
blood flow rate achieved was 243 mL/min, and the 
percentage of patients with Kt/V < 1.2 and URR < 65% 
were 56.7% and 65.2%, respectively [20]. This emphasizes 
the contribution of low blood flows to inadequate dialysis 
but also serves as a reminder that other variables such as 
age, pre-dialysis weight, time on dialysis and access recir-
culation play a role in the dialysis dose delivered [15,21]. 
The study reported a tendency to better performance 
with an AVF access (mean blood flow 330 mL/min and 
Kt/V 1.6) as compared to tunnelled catheters (mean blood 
flow rate 316 mL/min and Kt/V 1.5).  Similar findings were 
demonstrated by Canaud et al., where mean blood flow 
rates for AVF and tunnelled catheters were 340 mL/min 
and 316 mL/min, respectively, with higher Kt/V measure-
ments for patients with an AVF [22]. In a Canadian study of 
259 patients with a tunnelled HD catheter [15], the mean 
blood flow rate achieved was 352 mL/min and the pro-
portion of patients with URR < 65% was 10.5%. The better 
performance measures could be due to their practice of 
routine vascular access blood flow and dialysis dose 
measurements.  
Most of our patients underwent twice-weekly dialysis; the 
remainder dialysed less frequently, mainly for economic 
reasons. Dialysis sessions lasted a standard time of 4 hours 
for all patients. The recommendations for Kt/V of 1.2 or 
URR of at least 65% [23] are based on patients dialysing 
three times a week. The recommended dosing for twice-
weekly HD is Kt/V ≥ 2 [24]. This can be achieved by 
lengthening treatment times [25] and increasing blood 
flow rates. 
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AVF assessment by Doppler ultrasound revealed adequate 
flows in around half of our patients (53%). The percentage 
of stenosis (19%) was low compared with other studies at 
45.5% and 64% [26,27]. Thrombotic events in other studies 
ranged between 17% and 25% [28]. Two of our patients 
lost their AVF due to thrombosis; intervention to restore 
function could not be undertaken for financial reasons. The 
stenotic lesions were located on the venous side of the 
anastomosis in six patients; two patients had additional long 
stenotic lesions in the efferent vein. Aneurysms were 
common but did not interfere with the functioning of the 
AVF. Intervention would be considered for cosmetic 
purposes or when there is overlying skin thinning with risk 
of rupture [29].   
cONcLUsIONs
This study demonstrates that most haemodialysis vascular 
accesses in use at the KNH renal unit have adequate flow 
rates. Arteriovenous fistulae provided better blood flow 
rates and dialysis dose, but there is a need to implement 
routine surveillance and make interventional procedures 
affordable to prevent loss of access. Tunnelled catheters 
provided adequate blood flows and dialysis dosages that 
were comparable to arteriovenous fistulae. Non-tunnelled 
catheters delivered poor blood flow rates and dialysis dose 
and are in use for longer than the recommended duration. 
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